Chronic Myeloproliferative Disorders Terminated Phase 1 Trials for Nelarabine (DB01280)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004239506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver ImpairmentTreatment